ARGX — ARGENX SE
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1697862 ·
Belgium
Last close
$853.40
Market Cap
$53.07B
52W High
$933.99
52W Low
$666.79
ADV30
347,447
Next earnings
2026-07-23
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 1,298,000,000 | 1,177,000,000 | 394,000,000 | 366,000,000 | — | — | — |
| Dec 2025 | 1,287,877,000 | 1,138,190,000 | 359,557,000 | 532,950,000 | 8,682,698,000 | 3,491,289,000 | 1,359,606,000 |
| Sep 2025 | 1,126,961,000 | 1,017,535,000 | 349,970,000 | 344,258,000 | — | — | — |
| Jun 2025 | 947,961,000 | 837,214,000 | 203,841,000 | 245,358,000 | 7,175,592,000 | 2,085,976,000 | 1,079,840,000 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-279,769,000
Inventory
$473,530,000
Receivables
$1,657,059,000
ST Investments
$948,750,000
EBIT TTM
$1,506,193,000
Pretax Income TTM
$1,502,246,000
Interest Exp TTM
$3,947,000
Analysts
22
Yahoo Snapshot (yfinance, live)
Total Revenue
$4,742,469,120
EBITDA
$1,318,290,304
Free Cash Flow
—
Enterprise Value
$1,319,718,879,232
Total Cash
$4,440,038,912
Total Debt
$47,160,000
Shares Out
62,187,771
Trailing EPS
$22.55
Book Value
$4.73
ROE
—
ROA
—
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 4,153,482,000 | 1,054,615,000 | 1,292,035,000 | 8,682,698,000 | 1,359,606,000 | — | 685,192,000 |
| Dec 2024 | 2,190,231,000 | -17,844,000 | 833,040,000 | 6,202,522,000 | 704,239,000 | — | -82,747,000 |
| Dec 2023 | 1,226,316,000 | -420,638,000 | -295,053,000 | 4,542,458,000 | 444,951,000 | — | -420,327,000 |
| Dec 2022 | 410,746,000 | -723,919,000 | -709,594,000 | 3,134,261,000 | 320,562,000 | — | -862,807,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$36.45
Max Pain — expiry 2026-07-17
max pain strike: $840.00 · spot: $856.17 · call oi: 672 · put oi: 664
Expected Move to 2026-07-17:
±$60.80
(7.10%) —
implied range
$795.37 –
$916.97
· ATM straddle on $860.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RVMD | Revolution Medicines, Inc. | $36.04B | $169.51 | — |
| BIIB | BIOGEN INC. | $29.11B | $197.19 | — |
| MRNA | Moderna, Inc. | $24.20B | $61.00 | — |
| BNTX | BioNTech SE | $22.92B | $90.62 | — |
| GILD | GILEAD SCIENCES, INC. | $155.26B | $125.05 | — |
News headlines (Yahoo Finance, 1h cache)
Can Argenx Retake Its Record High — And A Buy Point — On A New Vyvgart Strategy?
2026-06-24 14:29 · Yahoo
argenx to Host Autoimmune Myositis R&D Webinar
2026-06-23 05:00 · Yahoo
Chronic Inflammatory Demyelinating Polyneuropathy Market Gains Traction During the Forecast Period (2026-2036) with Advancing Clinical Research Activities | DelveInsight
2026-06-18 14:01 · Yahoo
European Equities Traded in the US as American Depositary Receipts Rise in Wednesday Trading
2026-06-17 15:10 · Yahoo
argenx Eyes More VYVGART Growth as Pipeline Catalysts Near
2026-06-12 11:06 · Yahoo
European Equities Traded in US as ADRs Rise in Thursday Trading
2026-06-11 15:09 · Yahoo
Assessing argenx (ENXTBR:ARGX) Valuation After Strong Recent Share Price Momentum
2026-06-11 03:16 · Yahoo
Sanofi, An Argenx Rival, Bites The Dust — But A Third Biotech Took The Biggest Hit
2026-06-10 20:48 · Yahoo
TGTX Rises on Positive Phase I Data for Subcutaneous Briumvi in MG
2026-06-10 13:17 · Yahoo
ARGX Shares Gain Nearly 9% in a Month: Here's What You Need to Know
2026-06-10 12:09 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.